Sandoz, Inc. Recalls 13 Lots of Orphenadrine Citrate 100 mg ER Tablets


Pharmaceutical Recall Related Images

Best Brands Consumer Products Hand Sanitizers
cpap and bipap masks with magnets
elv control herbal supplement
Product Image Not Available
Product Image Not Available

Sandoz Inc. (“Sandoz”) is initiating a voluntary recall of 13 lots (listed below) of oral Orphenadrine Citrate 100 mg Extended Release (ER) Tablets to the consumer level. The presence of a nitrosamine (N-methyl-N-nitroso-2-[(2-methylphenyl)phenylmethoxy]ethanamine (NMOA or Nitroso-Orphenadrine)) impurity, which has the potential to be above the U.S. Food and Drug Administration (FDA)’s Acceptable Daily Intake (ADI) limit of 26.5 ng/day, was detected in the lots during recent testing. These 13 lots of Orphenadrine Citrate ER Tablets were shipped to customers from August 2019 to April 2021.

Nitrosamines are substances with carcinogenic potency (substances that could cause cancer) when present above the allowable exposure limits. While the use of product belonging to the recalled lots may represent a risk to patients, to date, Sandoz has not received any reports of adverse events related to the presence of a nitrosamine impurity in the lot.

Orphenadrine Citrate ER Tablets are used as an adjunct to rest, physical therapy and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. The product is packaged in 100-count and 1000-count bottles and was distributed nationwide in the USA to wholesalers and distributors.

Product NameNDC NumberLot NumberExpiration DateDate of Manufacture
Orphenadrine Citrate ER Tablets0185-0022-01JX641105/20225/24/2019
Orphenadrine Citrate ER Tablets0185-0022-01JX641305/20225/24/2019
Orphenadrine Citrate ER Tablets0185-0022-01KC072308/20228/21/2019
Orphenadrine Citrate ER Tablets0185-0022-01KC330308/20228/21/2019
Orphenadrine Citrate ER Tablets0185-0022-01KE434811/202211/6/2019
Orphenadrine Citrate ER Tablets0185-0022-01KE716911/202211/6/2019
Orphenadrine Citrate ER Tablets0185-0022-01KE434911/202211/6/2019
Orphenadrine Citrate ER Tablets0185-0022-01KL319903/20233/3/2020
Orphenadrine Citrate ER Tablets0185-0022-01KM007203/20233/3/2020
Orphenadrine Citrate ER Tablets0815-022-10KS3939+03/20233/3/2020
Orphenadrine Citrate ER Tablets0185-0022-01LA770410/202310/6/2020
Orphenadrine Citrate ER Tablets0185-0022-01LA770310/202310/6/2020
Orphenadrine Citrate ER Tablets0185-0022-01LA924311/202311/18/2020

+ 1,000-count bottle

This recall of Orphenadrine Citrate ER Tablets is specific to the lots listed above and does not apply to any other strengths of Sandoz Orphenadrine Citrate ER Tablets nor to other lot numbers of the product. Any product returned that is not associated with this recall will be destroyed, and no credit will be issued.

Sandoz is notifying its wholesalers and distributors by mail and is arranging for the return of all recalled product. Wholesalers and distributors that have Orphenadrine Citrate ER Tablets subject to this recall should immediately stop distribution of the recalled product and quarantine and return all recalled product in their inventory.

Consumers who have Orphenadrine Citrate ER Tablets being recalled should stop taking the recalled product and immediately consult with their physician to obtain another prescription. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Retailers and consumers should contact Sedgwick directly by phone at 844-491-7869 or email at sandoz4887@sedgwick.com to return the recalled product. Representatives are available Monday – Friday, 8:00 am – 5:00 pm ET.

To report an adverse reaction, please contact Sandoz by phone at (800) 525-8747 or by email at qa.drugsafety@sandoz.com. Customer service agents are available Monday – Friday from 8:30 am to 5:00 pm ET.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

  • Complete and submit the report Online
  • Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Original recall and updates at FDA


Related Posts

medical recall
Suntegrity Skincare Recalls Suntegrity Impeccable Skin Sunscreen Foundation
Suntegrity Skincare Recalls Suntegrity Impeccable Skin Sunscreen Foundation
penn herb company nature’s wonderland thyroid formula
Penn Herb Company Ltd Recalls Nature’s Wonderland Thyroid Formula
Penn Herb Company Ltd Recalls Nature’s Wonderland Thyroid Formula
medical recall
Integrity Products Recalls Ram It & To The Moon Capsules
Integrity Products Recalls Ram It & To The Moon Capsules
medline bed assist bar
Medline Industries Recalls 1.5 Million Adult Portable Bed Rails – Two Deaths Reported
Medline Industries Recalls 1.5 Million Adult Portable Bed Rails - Two Deaths Reported

Latest Posts

aahu barah logo
AAHU BARAH USA INC. Recalls 19 Boxes of Aahu Barah Apricot Roll
villa nueva interservices arepa de choclo
Villa Nueva Interservices LLC. Recalls “Arepas LA Mejor” 25 oz bags of Arepa de Choclo
medical recall
Suntegrity Skincare Recalls Suntegrity Impeccable Skin Sunscreen Foundation
penn herb company nature’s wonderland thyroid formula
Penn Herb Company Ltd Recalls Nature’s Wonderland Thyroid Formula
bambu lab a1 printer
Bambu Lab Recalls A1 3D Printers Due to Electric Shock and Fire Hazards

Leave a Reply

Your email address will not be published. Required fields are marked *

You Are Leaving Us

This link is being provided as a convenience and for informational purposes only it is not an endorsement or an approval of any of the products, services or opinions of the corporation or organization or individual.

Recallinsider.com bears no responsibility for the accuracy, legality or content of the external site or for that of subsequent links.